Clinical Trial Update: A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors [Phase 2]

View source ↗

Summary

This clinical trials update describes a multicenter, open-label Phase IIa study to evaluate the efficacy and safety of B1962 injections in advanced malignant so…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Colorectal Cancer
• Hepatocellular Carcinoma
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Small Cell Lung Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• B1962

Snippet

Sponsor: Tasly Biopharmaceuticals Co., Ltd. | Conditions: Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Status: NOT_YET_RECRUITING